SEARCH

SEARCH BY CITATION

References

  • 1
    Rosenthal E, Salmon-Ceron D, Lewden C et al. Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalite 2005 survey, ANRS EN19). HIV Med 2009; 10: 282289.
  • 2
    Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156: 271278.
  • 3
    Weber R, Sabin CA, Friis-Moller N et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166: 16321641.
  • 4
    Soto B, Sanchez-Quijano A, Rodrigo L et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26: 15.
  • 5
    Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008; 22: 19791991.
  • 6
    Gane EJ, Stedman CA, Hyland RH et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 2014; 146: 736743.e1.
  • 7
    Everson GT, Sims KD, Rodriguez-Torres M et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 2014; 146: 420429.
  • 8
    Sulkowski M, Pol S, Mallolas J et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013; 13: 597605.
  • 9
    Sulkowski MS, Sherman KE, Dieterich DT et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013; 159: 8696.
  • 10
    Hull M, Klein M, Shafran S et al. on behalf of The CIHR Canadian HIV Trials Network HIV/Hepatitis C Management and Treatment Guidelines Working Group. CIHR Canadian HIV Trials Network Co-Infection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults. Can J Infect Dis Med Microbiol [Special Article]. 2013; 24: 217238.
  • 11
    Fidler S, Anderson J, Azad Y et al. Position statement on the use of antiretroviral therapy to reduce HIV transmission, January 2013: the British HIV Association (BHIVA) and the Expert Advisory Group on AIDS (EAGA). HIV Med 2013; 14: 259262.
  • 12
    Myers RP, Ramji A, Bilodeau M, Wong S, Feld JJ. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol 2012; 26: 359375.
  • 13
    Brau N, Salvatore M, Rios-Bedoya CF et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44: 4755.
  • 14
    Qurishi N, Kreuzberg C, Luchters G et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362: 17081713.
  • 15
    Thompson MA, Aberg JA, Hoy JF et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308: 387402.
  • 16
    Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. [PDF]: Department of Health and Human Services; [updated February 2, 2013] Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf (accessed 2 December 2013).
  • 17
    Labarga P, Soriano V, Vispo ME et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007; 196: 670676.
  • 18
    Shafran SD. Early initiation of antiretroviral therapy: the current best way to reduce liver-related deaths in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2007; 44: 551556.
  • 19
    Hull MW, Rollet K, Odueyungbo A et al. Factors associated with discordance between absolute CD4 cell count and CD4 cell percentage in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2012; 54: 17981805.
  • 20
    Miller CL, Johnston C, Spittal PM et al. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Hepatology 2002; 36: 737742.
  • 21
    Grebely J, Raffa JD, Lai C et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat 2009; 16: 352358.
  • 22
    Urbanus AT, van de Laar TJ, Stolte IG et al. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. AIDS 2009; 23: F1F7.
  • 23
    Danta M, Dusheiko GM. Acute HCV in HIV-positive individuals – a review. Curr Pharm Des 2008; 14: 16901697.
  • 24
    Yaphe S, Bozinoff N, Kyle R, Shivkumar S, Pai NP, Klein M. Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review. Sex Transm Infect 2012; 88: 558564.
  • 25
    Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis 2013; 57 (Suppl 2): S39S45.
  • 26
    Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. AIDS 2011; 25: 399409.
  • 27
    Montaner JS. Treatment as prevention – a double hat-trick. Lancet 2011; 378: 208209.
  • 28
    Hagan LM, Wolpe PR, Schinazi RF. Treatment as prevention and cure towards global eradication of hepatitis C virus. Trends Microbiol 2013; 21: 625633.
  • 29
    Cooper CL, Mills E, Wabwire BO, Ford N, Olupot-Olupot P. Chronic viral hepatitis may diminish the gains of HIV antiretroviral therapy in sub-Saharan Africa. Int J Infect Dis 2009; 13: 302306.
  • 30
    Ladep NG, Agaba PA, Agbaji O et al. Rates and impact of hepatitis on human immunodeficiency virus infection in a large African cohort. World J Gastroenterol 2013; 19: 16021610.